US5700814A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sabeluzole oral suspensions
Assignee: Janssen Pharmaceutica NV
•
Filing: 1995-10-06
•
Granted: 1997-12-23
•
Expires: 2015-10-06
Abstract
Abstract PCT No. PCT/EP95/03966 Sec. 371 Date Mar. 27, 1997 Sec. 102(e) Date Mar. 27, 1997 PCT Filed Oct. 6, 1995 PCT Pub. No. WO96/11687 PCT Pub. Date Apr. 25, 1996An aqueous suspension for oral administration comprising sabeluzole and a pharmaceutically acceptable carrier, having a pH in the range from 8 to 10; processes for preparing the same.
Inventors
- 👤 Marc Karel Jozef François
- 👤 Christine Frieda Augusta Agemans
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 03:13
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0087; A61K9/0095; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/445; A61K31/4523; A61K31/454
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
23 words
An aqueous suspension for oral administration comprising sabeluzole and a pharmaceutically acceptable carrier, having a pH in the range from 8 to 10.
Claim 2
Dependent Claim
23 words
An aqueous suspension for oral administration comprising sabeluzole and a pharmaceutically acceptable carrier, having a pH in the range from 8 to 10.
Claim 3
Dependent Claim
14 words
A suspension according to claim 1 wherein the active ingredient is sabeluzole polymorph I.
Claim 4
Dependent Claim
31 words
A suspension according to claim 1 wherein the pH range from 8 to 10 is created with a carbonate buffer comprising sodium carbonate, sodium bicarbonate and/or sodium hydroxide or hydrochloric acid.
Claim 5
Dependent Claim
12 words
A suspension according to claim 3 wherein the pH is approximately 9.
Claim 6
Dependent Claim
11 words
A suspension according to claim 1 further comprising a suspending agent.
Claim 7
Dependent Claim
21 words
A suspension according to claim 5 wherein the suspending agent is Avicel RC591® in an amount of 0.1 to 2% (w/v).
Claim 8
Dependent Claim
10 words
A suspension according to claim 1 further comprising a sweetener.
Claim 9
Dependent Claim
23 words
A suspension according to claim 7 wherein the sweetener is a sorbitol solution (70% (v/v)) in an amount of 5 to 30% (w/v).
Claim 10
Dependent Claim
61 words
A suspension according to claim 1 comprising (a) 0.01 to 5% (w/v) sabeluzole polymorph I; (b) 0.2 to 4% (w/v) suspending agents; (c) up to 30% (w/v) sweeteners; (d) up to 30% (v/v) preservatives; (e) 0.01 to 1% (w/v) wetting agent; (f) buffer substances to fix the pH in the range from 8 to 10; and (g) water q.s. ad 100%.
Claim 11
Dependent Claim
70 words
A suspension according to claim 9 comprising: (a) 0.05 to 1% (w/v) sabeluzole polymorph I; (b) 0.8 to 1.5% (w/v) dispersible cellulose and optionally 0.1 to 0.5% (w/v) hypromellose; (c) 10 to 30% (v/v) sorbitol solution; (d) 10 to 30% (v/v) propylene glycol; (e) 0.01 to 1% (w/v) polysorbate 20; (f) buffer substances to fix the pH in the range from 8.5 to 9.5; and (g) water q.s. ad 100%.
Claim 12
Dependent Claim
58 words
A suspension according to claim 10 comprising (a) 0.1% (w/v) sabeluzole polymorph I; (b) 1.2% (w/v) dispersible cellulose and optionally 0.25% (w/v) hypromellose; (c) 20% (v/v) sorbitol 70% (w/w) solution; (d) 20% (v/v) propylene glycol; (e) 0.025% (w/v) polysorbate 20; (f) sodium carbonate and hydrochloric acid to fix the pH at about 9; (g) water q.s. ad 100%.
Claim 13
Dependent Claim
25 words
A method of treating hypoxic or anoxic conditions in patients which comprises administering to such patients an effective amount of the suspension of claim 1.
Claim 14
Dependent Claim
25 words
A method of treating hypoxic or anoxic conditions in patients which comprises administering to such patients an effective amount of the suspension of claim 2.
Claim 15
Dependent Claim
25 words
A method of treating hypoxic or anoxic conditions in patients which comprises administering to such patients an effective amount of the suspension of claim 3.
Claim 16
Dependent Claim
25 words
A method of treating hypoxic or anoxic conditions in patients which comprises administering to such patients an effective amount of the suspension of claim 4.
Claim 17
Dependent Claim
25 words
A method of treating hypoxic or anoxic conditions in patients which comprises administering to such patients an effective amount of the suspension of claim 5.
Claim 18
Dependent Claim
25 words
A method of treating hypoxic or anoxic conditions in patients which comprises administering to such patients an effective amount of the suspension of claim 6.
Claim 19
Dependent Claim
25 words
A method of treating hypoxic or anoxic conditions in patients which comprises administering to such patients an effective amount of the suspension of claim 7.
Claim 20
Dependent Claim
25 words
A method of treating hypoxic or anoxic conditions in patients which comprises administering to such patients an effective amount of the suspension of claim 8.
Claim 21
Dependent Claim
25 words
A method of treating hypoxic or anoxic conditions in patients which comprises administering to such patients an effective amount of the suspension of claim 9.
Claim 22
Dependent Claim
25 words
A method of treating hypoxic or anoxic conditions in patients which comprises administering to such patients an effective amount of the suspension of claim 10.
Claim 23
Dependent Claim
25 words
A method of treating hypoxic or anoxic conditions in patients which comprises administering to such patients an effective amount of the suspension of claim 11.
References Cited (Backward Citations)
US4861785A
Cited
US5434168A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-12-22 | 2001-06-23 | 2001-12-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-12-22 | 2005-06-23 | 2005-12-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-12-22 | 2009-06-23 | 2009-12-23 | $7700.00 | Window Closed / Lapsed |